The current study reports on genomic alterations of GPR139 and GPR142 through tumor samples, assisting in the identification of common drug compounds for GPR142 target by 3D database by scanning common pharmacophoric features and experimental EC50 value which might be useful in the inhibition of cancer. Here, GPR139 is linked to cancer.